Brandon M Huffman - Division of GI Oncology, Dana-Farber Cancer Institute;Adham Jurdi, Natera, Inc;Department of Medicine, Massachusetts General Hospital Cancer Center;Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 107 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Preliminary Phase 1/1b Dose Expansion Results of the Bifunctional EGFR/TGFβ Inhibitor Ficerafusp Alfa (BCA101) with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Anal Canal

Van K. Morris,Brandon Huffman,Cathy Eng, Rita P. Dalal,Rachel Salazar,David Bohr, Kaitlin H. Morton,Philippe Bedard

Journal of Clinical Oncologyno. 4_suppl (2025): 4-4

Cited0Views0Bibtex

A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

CANCER IMMUNOLOGY RESEARCHno. 1 (2025): 9-22

Cited0Views0WOSBibtex

Supplementary Figure 3 from ras/raf Comutation and erbb2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

openalex

Cited0Views0Bibtex

Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 9 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Circulating Tumor DNA As a Prognostic Biomarker for Recurrence in Patients with Locoregional Esophagogastric Cancers with a Pathologic Complete Response

Eric Michael Lander,Vasily N. Aushev,Brandon M. Huffman,Diana Hanna,Punashi Dutta,Jenifer Ferguson,Shruti Sharma,Adham Jurdi,Minetta C. Liu,Cathy Eng,Samuel J. Klempner,Michael K. Gibson

JCO PRECISION ONCOLOGY (2024)

Cited0Views0WOSBibtex

Supplementary Table 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Supplementary Methods 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn